Cell and Gene Therapy Today—July 9, 2026

LucidQuest

8 hours ago

This week’s Gene and Cell Therapy update highlights regulatory progress, clinical advances, strategic partnerships, financing activity, and infrastructure expansion across multiple therapeutic areas.

In Today’s Newsletter

Dive deeper

🧬 CASGEVY expanded to ages 2+ in US [1] [US • 01 Jul 2026]

https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment
Context: Vertex said about 5,500 additional children in the US are now eligible, with 75+ activated US treatment centers.
Key point: Vertex said FDA approved CASGEVY for people ages 2+ with SCD with recurrent VOCs or TDT.
Implication: May expand screening, initiation, and follow-up at scale.

🧠 Itvisma approved in EU for broader SMA population [2] [EU • 02 Jul 2026]

https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-itvisma-spinal-muscular-atrophy-sma
Context: Approval was based on STEER, with supportive STRENGTH and STRONG data; STEER reported sustained HFMSE improvement over 52 weeks.
Key point: Novartis said the European Commission approved Itvisma for children 2+, teens, and adults with 5q SMA and bi-allelic SMN1 mutation.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ Catalent and Nanoscope expand MCO-010 supply partnership [3] [US • 07 Jul 2026]

https://www.prnewswire.com/news-releases/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010-302819035.html
Context: Nanoscope said a rolling FDA BLA submission is underway for MCO-010 in retinal degenerative diseases.
Key point: Catalent will support commercial-compliant packaging and distribution for Nanoscope’s MCO-010.
Implication: Signals pipeline investment and modality expansion.

🤝 GC Cell launches Korean CGT value-chain alliance [4] [Korea • 08 Jul 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=32349
Context: The alliance spans CDMO, GMP manufacturing, RA, CMC consulting, media, toxicology, viral vectors, and bioanalysis.
Key point: GC Cell signed an MoU with Xcell Therapeutics, CorestemChemon, Genemedicine, and GCCL.
Implication: Signals pipeline investment and modality expansion.

💰 MeiraGTx secures Oberland Capital financing [5] [07 Jul 2026]

https://www.fiercebiotech.com/biotech/meiragtx-scores-400m-oberland-capital-help-get-2-gene-therapies-commercialization
Context: Funding is tied to botaretigene sparoparvovec and AAV2-hAQP1, with milestone tranches linked to FDA approvals and AQUAx2 data.
Key point: MeiraGTx secured up to $400M from Oberland Capital to support late-stage gene therapies.
Implication: Signals pipeline investment and modality expansion.

🧫 United Therapeutics buys Thymmune Therapeutics [6] [03 Jul 2026]

https://www.fiercebiotech.com/biotech/united-therapeutics-pays-140m-thymic-cell-therapy-startup
Context: Thymmune’s lead preclinical candidate, THY-100, uses iPSC-derived thymic cells for congenital athymia.
Key point: United Therapeutics paid $140M upfront to acquire Thymmune Therapeutics, with up to $160M in milestones.
Implication: Signals pipeline investment and modality expansion.

🦠 LucasBio and Institut Pasteur Korea advance SFTS T-cell candidate [7] [Korea • 03 Jul 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=32299
Context: Studies were conducted in a BSL-3 lab; no approved SFTS vaccine or treatment is currently available worldwide.
Key point: LucasBio and Institut Pasteur Korea said LB-DTK-SFTSV selectively eliminated SFTSV-infected cells in preclinical testing.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ Emmecell wins RMAT designation for EO2002 [8] [US • 07 Jul 2026]

https://www.businesswire.com/news/home/20260707252144/en/Emmecell-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-EO2002-for-the-Treatment-of-Corneal-Endothelial-Disease
Context: EO2002 is an investigational allogeneic cultured human corneal endothelial cell therapy using Magnetic Cell Delivery.
Key point: FDA granted RMAT designation to Emmecell’s EO2002 for corneal edema secondary to corneal endothelial dysfunction.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Regulators are extending CGT access into younger and broader patient populations, including CASGEVY in the US and Itvisma in the EU.
Ophthalmology remains a major CGT focus, spanning MCO-010, bota-vec, AAV2-hAQP1, and EO2002.
Korean groups are building CGT infrastructure across manufacturing, vectors, toxicology, and bioanalysis.
Financing and M&A continue to support late-stage assets and preclinical regenerative platforms.
Infectious disease cell therapy is emerging as a rapid-response concept, but LucasBio and IPK remain preclinical.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What changed for CASGEVY (Vertex)?

FDA expanded CASGEVY to people ages 2+ with SCD with recurrent VOCs or TDT in the US. Vertex said about 5,500 additional children are now eligible. [1]

What is Itvisma (Novartis)?

Itvisma is onasemnogene abeparvovec, a one-time fixed-dose gene replacement therapy for 5q SMA. The EC approval covers children 2+, teens, and adults with a bi-allelic SMN1 mutation. [2]

What role will Catalent play for MCO-010 (Nanoscope)?

Catalent will provide commercial-compliant packaging and distribution for MCO-010. The partnership supports Nanoscope’s rolling FDA BLA submission. [3]

What is the GC Cell alliance meant to do?

GC Cell and four Korean partners aim to create an end-to-end CGT support system. The alliance covers manufacturing, media, toxicology, viral vectors, and bioanalysis. [4]

Which MeiraGTx programs are tied to the Oberland Capital financing?

The financing is tied to botaretigene sparoparvovec for XLRP and AAV2-hAQP1 for radiation-induced xerostomia. Milestones are linked to FDA approvals and AQUAx2 data. [5]

What does RMAT designation mean for EO2002 (Emmecell)?

RMAT designation gives Emmecell more opportunities for interaction with FDA during EO2002 development. The therapy targets corneal edema secondary to corneal endothelial dysfunction. [8]

Entities / Keywords

Vertex Pharmaceuticals, CASGEVY, exagamglogene autotemcel, sickle cell disease, SCD, vaso-occlusive crises, VOCs, transfusion-dependent beta thalassemia, TDT
Novartis, Itvisma, onasemnogene abeparvovec, spinal muscular atrophy, SMA, 5q SMA, SMN1, STEER, STRENGTH, STRONG
Catalent, Nanoscope Therapeutics, MCO-010, optogenetic gene therapy, retinitis pigmentosa, Stargardt disease, BLA
GC Cell, Xcell Therapeutics, CorestemChemon, Genemedicine, GCCL, CGT CDMO, GMP, RA, CMC, viral vectors, bioanalysis
MeiraGTx, Oberland Capital, botaretigene sparoparvovec, bota-vec, XLRP, AAV2-hAQP1, xerostomia, AQUAx2
United Therapeutics, Thymmune Therapeutics, THY-100, iPSC-derived thymic cells, congenital athymia, neo-thymus
LucasBio, Institut Pasteur Korea, LB-DTK-SFTSV, SFTS, SFTSV, DTK platform, memory T-cell therapy, BSL-3
Emmecell, EO2002, RMAT, Magnetic Cell Delivery, corneal endothelial disease, corneal edema, EMERALD